The American Medical Association on Wednesday will host a webinar on Tecovirimat (“TPOXX”) for treatment of monkeypox in infected individuals.

During the webinar, AMA Board Chair Sandra Fryhofer, M.D. will host experts from the Food and Drug Administration (FDA) and Centers for Disease and Control and Prevention (CDC) to provide media and physicians background on tecovirimat, including its current status, availability and access while the drug is under an investigational new drug application. A moderated question and answer session will be held at the end of the discussion to help address any confusion or misinformation about patient access to TPOXX.

 
What:    AMA webinar: Tecovirimat (“TPOXX”) for Treatment of Monkeypox

When:   Wednesday, September 13, 2022, 11 a.m. Central | noon Eastern

Who:     Sandra Fryhofer, MD, Chair, AMA Board of Trustees

Adam Sherwat, MD, Deputy Director, Office of Infectious Disease at FDA’s Center for Drug Evaluation and Research

Brett W. Petersen, MD, MPH, Deputy Chief, Poxvirus and Rabies Branch, CDC’s Division of High-Consequence Pathogens and Pathology

Timothy Wilkin, MD, MPH, Professor of Medicine and Assistant Dean for Clinical Research Compliance for Human Research Protections at Weill Cornell Medicine and TPOXX clinical trial lead

Registration: To watch the live webinar, register here